Preclinical Evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System

Patzer, John F.; Mazariegos, George; López, Roberto

doi:10.1016/s1072-7515(02)01277-2

Cited by 31 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, PT in the BAL group was shorter than that in the sham BAL group. This indicated that porcine hepatocytes in the NWF-bioreactor did synthesize some of the vitamin K-dependent clotting factors, which is consistent with studies by Patzer et al [43]. However, the decreased platelet was not improved by the BAL treatment.…”

Section: Discussionsupporting

confidence: 89%

Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs

Zhang

et al. 2006

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs

Zhang

et al. 2006

Journal of Hepatology

View full text Add to dashboard Cite

“…As ALF is a multisystem disorder including encephalopathy [4] and coagulopathy [5], critical care management of the ALF continues to be one of the most challenging problems in clinical medicine [6,7]. Artificial [8,9] and bioartificial [10] liver assist devices have been developed to replace aspects of liver functionality and prolong survival until spontaneous recovery or as a bridge to liver transplantation [11,12]. There is an unmet clinical need to provide a relevant, reproducible large animal model of acetaminophen-induced ALF in which to test putative therapies such as novel hepatic support systems or new pharmacological agents designed to address these issues.…”

Section: Introductionmentioning

confidence: 99%

A Reproducible Porcine Model of Acute Liver Failure Induced by Intrajejunal Acetaminophen Administration

Thiel

Thiel²,

Etspueler³

et al. 2011

Eur Surg Res

View full text Add to dashboard Cite

Background and Aims: Severe intoxication following acetaminophen overdose is the most common cause of acute liver failure (ALF) in many Western European and North American countries. A reproducible large animal model of acetaminophen intoxication has not been successfully evaluated previously. Methods: Eight male pigs underwent acetaminophen intoxication receiving an initial enteric bolus of 250 mg/kg body weight acetaminophen followed by an acetaminophen plasma level (300–450 mg/l) adapted enteric maintenance dose of 1,000–3,000 mg/h to the onset of ALF (prothrombin time value <30%). Vital and ventilation parameters were continuously recorded until death. Saline, hydroxyethyl starch, fresh frozen plasma and erythrocyte units were used for volume substitution, and norepinephrine to prevent severe hypotension. Results: All animals developed ALF after 25 ± 3 h, which was confirmed by laboratory values, the clinical course and histological examinations. All animals died due to ALF after a further 21 ± 5 h, precipitated by cerebral edema. Conclusions: Using an initial enteric acetaminophen bolus, followed by body weight-adapted acetaminophen plasma level intoxication, it was possible to establish a reproducible, clinically relevant porcine model which may be used for the investigation of novel therapeutic approaches in this life-threatening condition.

show abstract

“…Presently, several BAL systems have already undergone phase I clinical trials, and some have even undergone phase II/III clinical trials, but all without satisfactory results [24,25,[38][39][40][41].…”

Section: Current Application Of Balmentioning

confidence: 99%

Bioartificial liver devices: Perspectives on the state of the art

Ding

Shi

2010

Front. Med.

View full text Add to dashboard Cite

Acute liver failure remains a significant cause of morbidity and mortality. Bioartificial liver (BAL) devices have been in development for more than 20 years. Such devices aim to temporarily take over the metabolic and excretory functions of the liver until the patients' own liver has recovered or a donor liver becomes available for transplant. The important issues include the choice of cell materials and the design of the bioreactor. Ideal BAL cell materials should be of good viability and functionality, easy to access, and exclude immunoreactive and tumorigenic cell materials. Unfortunately, the current cells in use in BAL do not meet these requirements. One of the challenges in BAL development is the improvement of current materials; another key point concerning cell materials is the coculture of different cells. The bioreactor is an important component of BAL, because it determines the viability and function of the hepatocytes within it. From the perspective of bioengineering, a successful and clinically effective bioreactor should mimic the structure of the liver and provide an in vivo-like microenvironment for the growth of hepatocytes, thereby maintaining the cells' viability and function to the maximum extent. One future trend in the development of the bioreactor is to improve the oxygen supply system. Another direction for future research on bioreactors is the application of biomedical materials. In conclusion, BAL is, in principle, an important therapeutic strategy for patients with acute liver failure, and may also be a bridge to liver transplantation. It requires further research and development, however, before it can enter clinical practice.

show abstract

Preclinical Evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System

Cited by 31 publications

References 18 publications

Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs

Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs

A Reproducible Porcine Model of Acute Liver Failure Induced by Intrajejunal Acetaminophen Administration

Bioartificial liver devices: Perspectives on the state of the art

Contact Info

Product

Resources

About